phenyl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester | 849109-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester
• 英文别名: [6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)naphthalen-2-yl] N-phenylcarbamate
• CAS: 849109-60-0
• 化学式: C₃₁H₂₂N₄O₂
• 分子量: 482.541
• InChiKey: IMDDYPPGAFMEKM-UHFFFAOYSA-N

物化性质

• 沸点：
  701.5±60.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Sulfonamides for treatment of endothelin-mediated disorders
  申请人：——

  公开号：US20020091270A1

  公开（公告）日：2002-07-11

  Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

  提供了噻唑磺胺及其药用可接受衍生物、药物组合物、制造物品、组合物、冻干粉剂以及使用这些配方和磺胺类药物治疗内皮素疾病的方法。提供了一种制备疏水性磺胺类化合物的碱金属盐的过程。该过程包括将游离磺胺类化合物溶解在有机溶剂中，在饱和的碱金属盐溶液存在下，并从有机相中回收形成的磺胺类盐的步骤。
• Compounds and compositions as protein kinase inhibitors
  申请人：Gray S. Nathanael

  公开号：US20050209285A1

  公开（公告）日：2005-09-22

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.

  本发明提供了一类新型化合物，包括含有这些化合物的药物组合物和使用这些化合物治疗或预防与异常或非调节激酶活性相关的疾病或障碍的方法，特别是涉及Abl、BCR-Abl、PDGF-R、lck、SAPK2α、p38、TGFβ、KDR、c-Kit、b-RAF、c-RAF、FLT1和FLT4激酶异常激活的疾病或障碍。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Gray Nathanael S.

  公开号：US20090258910A1

  公开（公告）日：2009-10-15

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或调节酪氨酸激酶活性相关的疾病或紊乱，特别是涉及Abl、BCR-Abl、PDGF-R、lck、SAPK2α、p38、TGFβ、KDR、c-Kit、b-RAF、c-RAF、FLT1和FLT4激酶异常激活的疾病或紊乱的方法。
• Process for preparing alkali metal salts of hydrophobic sulfonamides
  申请人：ENCYSIVE PHARMACEUTICALS INC.

  公开号：EP1498419A1

  公开（公告）日：2005-01-19

  Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods of altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolysulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic plant.

  本发明提供了噻吩基、呋喃基和吡咯基磺酰胺类化合物、磺酰胺类化合物的药学上可接受的盐、盐和磺酰胺类化合物的制剂，以及使用这些制剂和磺酰胺类化合物改变内皮素族肽活性的方法。特别是提供了 N-(异恶唑基)噻吩基磺酰胺、N-(异恶唑基)呋喃基磺酰胺和 N-(异恶唑基)吡咯基磺酰胺的钠盐制剂。提供了一种制备疏水磺酰胺碱金属盐的工艺。该工艺包括在有饱和碱金属盐溶液存在的情况下，将游离磺酰胺溶解在有机溶剂中，并从有机植物中回收形成的磺酰胺盐。
• SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS
  申请人：ENCYSIVE PHARMACEUTICALS INC.

  公开号：EP0980369B1

  公开（公告）日：2005-03-30